Pharmaceutical composition containing prulifloxacin, and preparation method thereof

A technology of prulifloxacin and composition, which is applied in the field of pharmaceutical compositions containing prulifloxacin and its preparation, can solve the problems of affecting the safety and effectiveness of this product, reducing active pharmaceutical ingredients, increasing related substances and the like
CN102240290BActive Publication Date: 2013-10-30SUZHOU DAWNRAYS PHARM CO LTD
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SUZHOU DAWNRAYS PHARM CO LTD
Publication Date
2013-10-30

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of pharmaceutical preparations, in particular to a pharmaceutical composition containing prulifloxacin, and a preparation method thereof. The pharmaceutical composition is characterized by containing prulifloxacin and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier at least comprises phosphate, and the weight ratio of the prulifloxacin to the phosphate is (1:2)-(2:1). Shown by stability tests, the impurity content of the pharmaceutical composition provided by the invention is obviously lower than that of a common preparation.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of pharmaceutical preparations, in particular to a pharmaceutical composition containing prulifloxacin and a preparation method thereof. Background technique

[0002] Prulifloxacin, its chemical name is: (±)-6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxole- 4-yl)-methyl-1-piperidinyl]-4-oxo-4hydro-[1,3]thiazine[3,2-a]quinoline-3-carboxylic acid. Its structural formula is as follows:

[0003]

[0004] This product is developed by Meiji Pharmaceutical Company of Japan. It belongs to the fourth generation of quinolone antibiotics. It is the prodrug of NM394. It inhibits the activity of bacterial DNA topoisomerase II and IV, inhibits the synthesis of bacterial DNA, and completes the bactericidal effect. Compared with the traditional bactericidal mode, there is no resistance to other types of antibiotics. The drug has a wide antibacterial spectrum, and has significant curative effect on both Gram-negative bacteria ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More